NVRO Stock Recent News

REDWOOD CITY, Calif. , Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on September 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 51,543 shares of Nevro's common stock to 21 new non-executive employees to induce them to accept employment with Nevro.

REDWOOD CITY, Calif. , Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024, beginning at 8:45 a.m.

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

REDWOOD CITY, Calif. , Aug. 14, 2024  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on August 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 10,199 shares of Nevro's common stock to four new non-executive employees to induce them to accept employment with Nevro.

Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. The company has seen an eventful decade with huge share price fluctuations, but the situation is quite severe right now. Competitive pressures hurt the topline sales, as the loss rate is very substantial, leaving few opportunities to grow out of this situation here.

Nevro's (NVRO) second-quarter earnings beat the Zacks Consensus Estimate while worldwide revenues decline year over over. The company incurs a loss at the operating level.

Nevro Corp. (NYSE:NVRO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Angie McCabe - VP, IR & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Nathan Treybeck - Wells Fargo Robbie Marcus - JPMorgan Brandon Vazquez - William Blair Anthony Petrone - Mizuho Bill Plovanic - Canaccord David Rescott - Baird Operator Good afternoon. My name is Mark, and I will be your conference operator today.

Nevro (NVRO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.69 per share a year ago.

Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif. , Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second-quarter 2024 financial results, revised its full-year 2024 guidance, and issued third-quarter 2024 guidance.

REDWOOD CITY, Calif. , July 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on July 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 69,201 shares of Nevro's common stock to 17 new non-executive employees to induce them to accept employment with Nevro.